Business Wire

Vaultree Appoints Technology Industry Veteran Rinki Sethi to Its Board of Directors

14.2.2023 16:03:00 EET | Business Wire | Press release

Share

Vaultree, the Data-In-Use Encryption leader, today announced the appointment of Rinki Sethi to the company's board of directors.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230214005299/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Rinki Sethi joins Vaultree Board of Advisors (Photo: Business Wire)

Rinki Sethi is the current vice president and chief information security officer at BILL, where she leads global information technology functions. She is also responsible for leading efforts to protect BILL’s information and technology assets and advise the company’s continued innovations in the security space.

Sethi brings decades of security and technology leadership expertise, including her recent roles as VP and CISO at Twitter and Rubrik, Inc. She has been at the forefront of developing cutting edge online security infrastructure at several Fortune 500 companies such as IBM, Palo Alto Networks, Intuit, eBay, Walmart.com and PG&E. Sethi also serves on the board of ForgeRock, a global digital identity leader. She advises many other startups and VCs.

Sethi holds several recognized security certifications and has a B.S. in Computer Science Engineering from UC Davis and a M.S. in Information Security from Capella University.

“Bringing Rinki on board underscores our strong focus on innovation in the field. With Vaultree on the journey to solving major cryptographic problems around data security and encryption, it is incredibly important to us that we work with industry experts like Rinki to ensure we bring Data-In-Use Encryption to the forefront and enable businesses to significantly reduce the risks of plaintext data exposure,” said Ryan Lasmaili, CEO and co-founder of Vaultree. “Trust and confidence are other important pillars that Rinki will bring with her to support Vaultree in creating an encrypted future where plaintext data no longer exists, and Data-In-Use Encryption is the standard across all industries.”

In addition to its recent $12.8m Series A funding round, the appointment of Sethi will be instrumental in fulfilling Vaultree’s mission to protect the sensitive data of people and enterprises worldwide.

“I am joining Vaultree because I am very excited about their mission and how it will unleash the power of data by processing encrypted data. I am also very impressed by the team Vaultree has built and am looking forward to joining this journey with them,” said Rinki Sethi. “The idea is to democratize and demystify data privacy and encryption. As we move toward a world where every human will have ’privacy traces’ online, we are tackling a real-world issue. Data security is not only one of today's hot topics but also the topic of tomorrow.”

About Vaultree

Vaultree has developed the world’s first Fully Functional Data-in-Use Encryption solution that solves the industry’s fundamental security issue: persistent data encryption, even in the event of a leak. Vaultree enables enterprises, including those in the financial services and healthcare / pharmaceutical sectors, to mitigate the great financial, cyber, legal, reputational, and business risk of a data breach in plain text. With Vaultree, organizations process, search and compute ubiquitous data at scale, without ever having to surrender encryption keys or decrypt server-side. If a leak occurs, Vaultree’s data-in-use encryption persists, rendering the data unusable to bad actors. Integrating Vaultree into existing database technologies is seamless, requiring no technology or platform changes. Vaultree is a privately held company based in Ireland and the U.S. For more information, please visit www.vaultree.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Matt Culbertson
prforvaultree@bospar.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release

NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release

Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release

IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye